Nevis Brands Inc (PSCBF)

[TechStockReport]

Pascal Biosciences Announces New OTC Markets Trading Symbol PSCBF
Wed, June 2, 2021

VANCOUVER, BC / ACCESSWIRE / Pascal Biosciences Inc. ("Pascal" or the "Company") (TSXV:PAS)(OTC PINK:PSCBF, previously BIMUF), has today received a new Over The Counter (OTC) trading symbol following acceptance of Form 211 by the US Financial Industry Regulatory Authority (FINRA). The new symbol is PSCBF and better reflects the company name PaSCal Biosciences.

In addition, Pascal announced the Board of Directors has appointed Mark van der Horst as President. Mr. van der Horst has been the president of Gale Capital Corporation (Gale) since 1993. Gale has worked with numerous public companies in both Canada and the United States as a capital markets advisor. Most recently, Mark was CEO of two recently listed CSE companies, EyeFi Group Technologies Inc. (EGTI) and EonX Technologies Inc. (EONX) and was instrumental in their organization, listing and financing.

"We are making a concerted effort to increase our corporate communications in both Canada and the US. Further to that point, we are excited to welcome Mark van der Horst onboard as President. Mr. van der Horst brings over 30 years of North American capital markets experience and will be instrumental in creating greater investor awareness for Pascal." said CEO Patrick Gray.

FINRA is the US regulator responsible for OTC markets including the OTCBB and Pink Sheets. A company must file Form 211 with FINRA to comply with SEC Rule 15c2-11, which covers the requirements necessary for the initiation of electronic quotation of securities in the OTC Markets.

The completed Form 211 provides basic corporate information for review by FINRA.

ABOUT PASCAL BIOSCIENCES INC.

Pascal is a biotechnology company targeting innovative therapies for serious diseases, including COVID-19. Pascal is also developing treatments for cancer with targeted therapies for acute lymphoblastic leukemia and cannabinoid-based therapeutics. Pascal's leading portfolio also comprises a small molecule therapeutic, PAS-403, that is advancing into clinical trials for the treatment of glioblastoma, and PAS-393, an immuno-stimulatory cannabinoid to be used in combination with checkpoint inhibitor therapy which is being developed collaboratively with SoRSE Technology.

To learn more, visit: https://www.pascalbiosciences.com/.

On Behalf of the Board of Directors
Dr. Patrick W. Gray, CEO

Company Contact:
Dr. Patrick Gray

Investors:
[e-mail]
Tel: [phone]